Benchmark set a $65.00 price target on EXACT Sciences (NASDAQ:EXAS) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the medical research company’s stock.

Several other equities analysts have also recently issued reports on the company. Bank of America boosted their target price on EXACT Sciences from $58.00 to $67.00 and gave the stock a buy rating in a research report on Wednesday, November 29th. Leerink Swann reissued an outperform rating and set a $67.00 price target (up previously from $63.00) on shares of EXACT Sciences in a research note on Monday, November 13th. Robert W. Baird lowered EXACT Sciences from an outperform rating to a neutral rating and set a $56.00 price target on the stock. in a research note on Monday, November 13th. Canaccord Genuity reissued a buy rating and set a $60.00 price target (up previously from $45.00) on shares of EXACT Sciences in a research note on Tuesday, October 3rd. Finally, Jefferies Group boosted their price target on EXACT Sciences to $60.00 and gave the stock a buy rating in a research note on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. EXACT Sciences currently has a consensus rating of Buy and a consensus target price of $51.64.

EXACT Sciences (EXAS) traded down $0.97 during midday trading on Wednesday, reaching $47.82. The company’s stock had a trading volume of 4,770,280 shares, compared to its average volume of 2,808,867. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. EXACT Sciences has a 52 week low of $16.95 and a 52 week high of $63.60. The firm has a market cap of $5,725.49, a PE ratio of -41.22 and a beta of 0.68.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. research analysts predict that EXACT Sciences will post -1.09 earnings per share for the current year.

In related news, insider Kevin T. Conroy sold 125,402 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $52.79, for a total value of $6,619,971.58. Following the sale, the insider now owns 955,454 shares of the company’s stock, valued at approximately $50,438,416.66. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP D Scott Coward sold 1,665 shares of the company’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the sale, the senior vice president now directly owns 37,558 shares in the company, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 735,835 shares of company stock worth $40,961,278. 4.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of EXAS. Fred Alger Management Inc. purchased a new stake in EXACT Sciences in the 2nd quarter valued at approximately $84,177,000. Lord Abbett & CO. LLC lifted its stake in EXACT Sciences by 59.1% in the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after buying an additional 875,527 shares in the last quarter. Vanguard Group Inc. lifted its stake in EXACT Sciences by 8.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after buying an additional 700,051 shares in the last quarter. FMR LLC lifted its stake in EXACT Sciences by 32.7% in the 2nd quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after buying an additional 571,796 shares in the last quarter. Finally, Frontier Capital Management Co. LLC lifted its stake in EXACT Sciences by 163.0% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 916,713 shares of the medical research company’s stock valued at $43,196,000 after buying an additional 568,144 shares in the last quarter. 82.39% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/01/21/exact-sciences-exas-given-a-65-00-price-target-at-benchmark.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.